SynthesisInternational journal of clinical oncology2025
Association between increased proteinuria induced by Bevacizumab, Ramucirumab, and Aflibercept and the risk of renal impairment and failure: a systematic review and meta-analysis.
Synthesis in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment with bevacizumab, ramucirumab, and aflibercept increases the risk of developing proteinuria; however, their association with the risk of renal impairment or failure remains unknown, warranting further investigation.
methodsConsequently, a systematic review and meta-analysis were conducted to quantify the exact risk and incidence of proteinuria, renal impairment, and renal failure associated with bevacizumab, ramucirumab, and aflibercept therapy. We searched the PubMed, Cochrane Library, and Web of Science databases for phase III randomized controlled trials (RCTs) of these therapies published before November 5, 2024.
resultsThe meta-analysis included 29,165 patients from 47 RCTs, including 14,211 patients who received bevacizumab, ramucirumab, and aflibercept. The incidence of proteinuria was 24% (95% confidence interval [CI] 18-33) for all-grades and 3% (95% CI 2-4) for grades ≥ 3 proteinuria. Compared with controls, the addition of these medications was associated with an increased risk of developing all grades of proteinuria (odds ratio [OR]: 7.32; 95% CI 5.17-10.3), as well as grades ≥ 3 proteinuria (OR: 7.05; 95% CI 5.52-9.00). The risk of all-grade (OR: 1.54; 95% CI 1.21-1.96) and grade ≥ 3 (OR; 1.64, 95% CI 1.08-2.24) renal impairment significant increased with additional treatment with these drugs. However, no significant increase in risk was observed for renal failure at any grade (OR: 1.26; 95% CI 0.92-1.72).
conclusionBevacizumab, ramucirumab, and aflibercept significantly increased the risk of developing proteinuria and renal impairment, but not renal failure. Monitoring and managing renal function and proteinuria in patients treated with these drugs is crucial.
Indexed as
Identifiers
40616772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.